SpyGlass Pharma, Inc. SGP
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | 65 | 65 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | (13) | (29) | (40) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (13) | (29) | (40) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 1 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (7.66) | (16.31) | (17.98) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (7.06) | (12.32) | (14.75) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.12) | (1.11) | (0.36) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (7.19) | (13.43) | (15.11) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (18.98) | (33.82) | (44.58) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 2 | 2 | 2 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | (12) | (22) | (33) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | 0 | (2) | (1) |
Capex
|
|||
| — | — | — | — | — | — | — | (12) | (24) | (33) |
FCF
|
|||
| — | — | — | — | — | — | — | 39 | 10 | 100 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | (40) | (16) | (107) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (33) | (60) | (99) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (90.48%) | (57.29%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 62.41% | 50.05% |
ROE
|
|||
SpyGlass Pharma, Inc. (SGP) Latest News
27 Aug
SpyGlass Pharma opens new Irvine headquarters to prepare for first product launch and establish custom R&D space. Headquarters opening enables first product launch and R&D setup but does not alter core trajectory.
6 Aug
SpyGlass Pharma reported second quarter 2026 financial results and provided corporate updates. Quarterly financial results and updates directly inform on fiscal position and operational progress.
18 May
SpyGlass Pharma secures new add-on Category III CPT Code for its BIM-IOL System. New CPT code directly supports reimbursement and commercial rollout of core product.
14 May
SpyGlass Pharma reports first quarter 2026 financial results and provides corporate updates. Quarterly financial results and corporate updates typically affect near-term investor sentiment and valuation metrics.
26 Mar
SpyGlass Pharma reported fourth quarter and full year 2025 earnings and issued a corporate update. Quarterly earnings releases and corporate updates typically affect near-term financial perceptions and stock sentiment without guaranteeing long-term trajectory shifts.
9 Mar
SpyGlass Pharma announces positive topline 12-month Phase 1/2 trial results for its BIM-IOL System. Positive Phase 1/2 results for core BIM-IOL product candidate signal major progress toward commercialization and revenue potential.
9 Feb
SpyGlass Pharma closed its initial public offering with full exercise of the underwriters' option to purchase additional shares. Full underwriters' option exercise delivers extra capital and public market access that shifts SpyGlass Pharma's financial runway and investor base.
5 Feb
SpyGlass Pharma priced its initial public offering. IPO pricing enables major capital raise and public listing transition for SpyGlass Pharma.